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 Abstract 
 
Clinically effective gene therapy for Cystic Fibrosis has been a goal for over 20 years. A plasmid 
vector (pGM169) that generates persistent expression and reduced host inflammatory responses in 
mice has raised prospects for translation to the clinic. The UK CF Gene Therapy Consortium is 
currently evaluating long-term repeated delivery of pGM169 complexed with the cationic lipid GL67A 
in a large Multidose Trial.  This regulatory-compliant evaluation of aerosol administration of nine 
doses of pGM169/GL67A at monthly intervals, to the sheep lung, was performed in preparation for the 
Multidose Trial. All sheep tolerated treatment well with no adverse effects on haematology, serum 
chemistry, lung function or histopathology. Acute responses were observed in relation to 
bronchoalveolar cellularity comprising increased neutrophils and macrophage numbers 1 day post-
delivery but these increases were transient and returned to baseline. Importantly there was no 
cumulative inflammatory effect or lung remodelling with successive doses. Molecular analysis 
confirmed delivery of pGM169 DNA to the airways and pGM169-specific mRNA was detected in 
bronchial brushing samples at day 1 following doses 1, 5 and 9. In conclusion, nine doses of 
pGM169/GL67A were well tolerated with no significant evidence of toxicity that would preclude 
adoption of a similar strategy in CF patients.  
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 1. Introduction 
 
 The cloning of the Cystic Fibrosis Transmembrance Conductance Regulator (CFTR) gene in 1989 
sparked significant interest in the development of gene therapy for cystic fibrosis (CF) to the extent 
that CF was regarded as the gene therapy paradigm. Twenty four years and approximately 25 gene 
therapy clinical trials later [1], CF remains a disease where, for the majority of patients, the only 
treatments available are those that delay the inevitable and ultimately fatal decline in lung function. 
  
 The UK CF Gene Therapy Consortium (GTC) has continued to search for solutions to overcome 
some of the problems associated with gene therapy, developing non-viral formulations with improved 
plasmid DNA constructs that reduce inflammatory responses and increase the duration of expression 
in preclinical models [2]. A plasmid (pGM169) has been engineered that is free of CG dinucleotides 
and contains a codon- optimised CFTR cDNA driven by the hCEFI promoter (Elongation Factor 1a 
promoter with a Human Cytomegalovirus (CMV) enhancer and a synthetic Intron). Our preclinical 
programme identified the cationic liposome GL67A as the most efficient non-viral vector for delivery of 
the plasmid DNA to the lung [3].  Data from a single dose Phase IIa trial of pGM169/GL67A 
complexes in CF patients indicated that delivery was safe and in some patients demonstrated 
evidence of changes in transepithelial chloride conductance  towards, or into, the normal range which 
could persist for up to 13 weeks [4]. A question that has yet to be answered is whether the relatively 
low levels of expression of the delivered gene, produced by non-viral gene therapy [5], can lead to 
clinical benefit for CF patients ie. Improve lung function, if expression can be sustained long term.  
This question is particularly relevant considering the endogenously very low levels of normal CFTR 
expression in the lungs, and the comparatively large clinical benefit CF patients with even small 
degrees of residual CFTR expression demonstrate. This fact has led us, (the GTC), to conclude that 
until a Multidose Trial of sufficient duration is undertaken, this key question cannot be addressed. 
Based on data showing the duration of transgene expression in mice [2] and our single-dose trial [4] 
the Multidose trial includes dosing at 4-week intervals over the course of a year.  
 Since it has previously been shown that a single dose of pDNA/GL67A can result in a transient flu-
like syndrome in patients [5, 6] and a transient increase in bronchoalveolar lavage neutrophils in our 
sheep model [3], it is of key importance to demonstrate that none of these mild and transient 
responses are exacerbated by repeated administration. Further, we wished to ensure there was no 
accumulation of lipid-filled macrophages, or significant remodelling of lung architecture. In preparation 
for the Multidose clinical trial, we have therefore conducted this toxicology study (TS) in sheep - an 
animal with lung structure and size similar to that of humans.    
 The main objective of this sheep TS was to assess the toxicity of repeated doses of aerosolised 
pGM169/GL67A complexes. A 10ml dose was selected as this volume is the maximal dose being 
considered for application in the Multidose Trial. Nine doses were delivered over a 32-week period at 
intervals of 4 weeks in line with the EMA guidelines (European Medicines Agency 
CPMP/ICH/286/95)for minimum duration in support of a clinical study of longer than 6 months. Using 
translation-relevant toxicity indices we assessed whether there was any evidence of cumulative local 
or systemic toxicity, We also took this opportunity to evaluate pGM169 plasmid delivery and 
expression in the lungs using this system. 
 
  
2. Materials and methods 
 
2.1 Animals 
 
 All experiments were carried out with approval of appropriate local Ethics Committees and 
according to Home Office regulations. Suffolk Cross lambs, average 33-53 kg (average 42kg), were 
treated on arrival with a parasiticide (Cydectin) and a flukicide (Fasinex), both administered at the 
manufacturers recommended dosage. A repeat dose of Cydectin was administered approximately 14 
days later and then again 6 months later, again following the manufacturers recommended dose rate 
for each individual animal (0.1 ml /5 kg bodyweight). They were also treated with a Clostridial and 
Pasturella vaccine (Heptavac P) at the manufacturer’s recommended dose during the trial to comply 
with standard Roslin Institute animal husbandry. The animals underwent a preliminary examination 
involving bronchoscopic visualisation and bronchoalveolar lavage (BAL) under gaseous anaesthesia 
prior to treatment to confirm the absence of pre-existing pulmonary disease.  This preliminary BAL 
procedure was restricted to the accessory lobe (Right Apical, RA) which branches from the trachea 
proximal to the carina. The time between preliminary BAL and delivery was 2 weeks to minimize the 
likelihood of any effect on gene transfer.  Four castrated male and four females were randomly 
assigned to the active multidose gene therapy (MD_GT) group and the anaesthetic alone control 
(MD_CON) group respectively. The animals were housed in four groups of four with two additional 
’sentinel‘ (SEN) animals assigned to each pen to monitor health status since the accommodation was 
not pathogen-free. Pre-treatment bronchial brushings (BBr, n=4 per sheep), baseline blood sample 
and spirometry data were collected from all 24 animals. MD_GT and MD_CON animals were sampled 
as described in Figure 1 (additional detail in Supplementary Material online, Tables S1-S2). Blood and 
BAL samples were also collected from SEN animals at times corresponding to Doses 1, 5 and 9. A 
full set of measurements and samples was collected from SEN animals at necropsy.  
 
2.2 Gene Transfer Agent 
 
 This study employed GLP grade plasmid pGM169 (VGXi, Houston, Texas, USA),  
Lot#pGM169.07C006 (5.1mg/ml)  and Lot#pGM169.07F017(5.3mg/ml) and GL67A (Octoplus, Leiden, 
The Netherlands) Batch# 08K26701-01A. pGM169 contains a codon- optimised,CpG-free CFTR 
cDNA driven by the hCEFI promoter which is composed of the CpG-free Human CMV enhancer, the 
CpG-free Elongation Factor 1a promoter together with a CpG-free synthetic Intron. 
 
2.3 Aerosol delivery  
 
 Anaesthetised animals were dosed, by whole lung aerosol exposure via an endotracheal tube, 
once every 4 weeks for 32 weeks giving a duration of 9 months. This is consistent with the EMA 
guidelines for minimum duration in support of a clinical study of longer than 6 months. Anaesthetic 
controls were intubated and exposed to room air with ambient humidity for 1h to avoid any drying 
effect of bottled gas. This study employed a well characterised lung aerosol delivery model in which 
gene transfer agents aerosolised using PARI LC Plus nebulisers are delivered to anaesthetised 
sheep via an endotracheal tube using a negative pressure ventilation system [3, 7]. The 
pGM169/GL67A formulations were prepared as described [8] by mixing 5ml of pGM169 with 5 ml of 
GL67A and consisted of 2.64mg/mL plasmid DNA, and approximately 14.29mg/ml total lipid (GL67, 
DOPE, DMPE-PEG 5000) for a total of 16.93mg/mL combined test item product. This is equivalent to 
8mM plasmid DNA and 6mM GL67A [9]. Animals placed in sternal recumbency in a whole body 
respirator were exposed to 10ml of aerosolised pGM169/GL67A delivered via an endotracheal tube. 
 
2.4 Lung function analysis 
 
 Airway pressures were measured by connecting one side of a differential pressure transducer to a 
side port at the proximal end of the endotracheal tube, the other side of which was open to the 
atmosphere. Respiratory air flows were measured by a screen pneumotachograph linear to 5.0 L·s-1 
(F300L Mercury Electronics, UK) connected to the proximal end of the endotracheal tube. This 
pneumotachograph was connected to a sensitive differential pressure transducer. Flow and pressure 
transducers were calibrated by rotameter (KDG 2000, KDG Mobrey, Crawley, UK) and U-tube 
manometers respectively. Lung resistance and dynamic lung compliance, lung diffusion capacity 
[DLCO or transfer Factor TLCO], alveolar lung volume (VAeff), functional residual capacity (FRC) 
were all determined immediately pre-and post-exposure. DLCO measurements determine the 
efficiency of the lung at diffusion across the alveolar-capillary membrane. This test involved inhalation 
of air containing carbon monoxide (0.28%) and helium (14%) and breath held for 10 seconds, then 
rapidly exhaled. The exhaled gas from the single breath was analyzed on a Morgan Benchmark gas 
analyser to determine carbon monoxide absorption during the breath to assess diffusion capacity and 
the final exhaled concentration of helium to determine VAeff and FRC. DLCO (SB) data are adjusted 
for haemoglobin levels. Forced Expiration data were obtained using a 210 L steel drum serving as a 
vacuum reservoir necessary to elicit a forced expiration in the anaesthetized sheep. Connection 
between the reservoir and the proximal end of the endotracheal tube was effected by thick walled 
wide bore tubing with the timing and duration of connection controlled by manual operation of a large 
bore (19mm) fast acting (40ms) solenoid valve (Danfoss EV210B, M & M Controls, Manchester, UK). 
Vacuum pressure within the drum was achieved through operation of a vacuum pump and could be 
adjusted to and maintained at the appropriate level (-4 kPa; visualized using a U-tube manometer) by 
manually operated bleed and check valves. Following a period of tidal ventilation the Cuirass pump 
was disconnected from the negative pressure ventilator and the sheep allowed to exhale passively to 
functional residual capacity (FRC). Thereafter the lungs were slowly inflated to an airway pressure of 
4kPa and then allowed to passively exhale to FRC. The lungs were then again inflated to a pressure 
of 4kPa and the proximal end of the endotracheal tube connected to the vacuum reservoir. Solenoid 
actuation effected the rapid discharge of the lung vital capacity into the vacuum reservoir after which 
the solenoid was closed. The lungs, by which time were at residual volume, were then gradually re-
inflated to an airway pressure of 3kPa, before the forced vital capacity manoeuvre was repeated on a 
further two occasions. Signals derived from the pneumotachograph and inflation pressure were fed 
into a computer sampling at 512 Hz through an analog to digital conversion card (NI PCI-6221, 
National Instruments, TX, USA). A custom designed computer program (LabView, National 
Instruments, TX, USA) facilitated the real-time visualization of signals, data storage and the 
subsequent interactive analysis of flow-volume curves. Volume was obtained by digital integration of 
the flow signal from the pneumotachograph. Post-hoc flow signal processing consisted of 4th-order 
Butterworth low-pass (15Hz) filtering. Forced vital capacity (FVC) was calculated as the expired 
volume between the lung volume at +4kPa inspiratory pressure and residual volume. As well as the 
maximal expiratory flow recorded at the start of expiration (MEF), the maximal expiratory flows at 
75%, 50%, 25% and 10% FVC near-residual volume (MEF75, MEF50, MEF25 and MEF10 
respectively) were measured, as were the forced expired volumes in 0.5 and 1 sec (FEV0.5 and 
FEV1) and the ratios formed by their relationship with FVC (FEV0.5/FVC and FEV1/FVC). The 
average flow between 75%, and 25% FVC near-residual volume was also measured (FEF25-75) as 
was a rate constant between 50% and 25% FVC near-residual volume (RC50-25; calculated as 
(MEF50 – MEF25)/(MEV50- MEV25) where MEV50 and MEV25 are the lung volumes at 50% and 
25% FVC near-residual volume). Forced ventilation parameters including Maximum and Average 
Expired Flow (MEF, AEF), Total Expired Volume (FVC) and Forced Expiratory Volume (FEV) were 
measured before each of the nine doses, at days 1 and 15 post-Dose 1, 5 and 9 and at 4 weeks after 
the final dose. 
 
2.5 Multiple Breath Washout/Lung Clearance Index 
 
 Inert gas multiple breath washout (MBW) involves continuously breathing in a small concentration 
of tracer gas over a short period of time until equilibrium is reached and then breathing in air while 
monitoring the concentration of the tracer gas during each expiration until the tracer gas is virtually 
undetectable in the exhalate [10]. Measuring gas flow concurrently with gas concentration allows 
various indices to be derived from the MBW data, including the Functional Residual Capacity (FRC) 
and the Lung Clearance Index (LCI). LCI is a measure of the unevenness of the distribution of 
ventilation, also called ventilation inhomogeneity. The higher the LCI, the greater the ventilation 
inhomogeneity. The protocol was adapted from the standard operating procedure currently used in a 
Single Dose Clinical Trial in humans. The tracer gas used in the MD Toxicology study was sulphur 
hexafluoride (SF6) at a concentration of 0.2% (supplied by BOC Industrial Gases, UK). An Innocor 
device was used to measure flow and the gas concentrations of SF6, CO2 & O2, with a frequency of 
100Hz, using its differential pressure transducer, photoacoustic gas analyser and oxigraph. The 
Innocor’s differential pressure transducer was connected via flexible gas tubes to a Series 4700A 
Hans Rudolph non-heated linear pneumotachometer. The pneumotachometer was modified to 
incorporate a gas sampling line, connected to the Innocor via Nafion tubing. A single-use antimicrobial 
filter was placed between the sheep’s endotracheal (ET) tube and the pneumotachometer for each 
test. The Innocor’s flowmeter was calibrated and the flow-gas delay calculated prior to each test 
session. 
MBW was performed following a period of stabilisation of negative-pressure ventilator parameters 
after the above Lung Function Tests had been performed and an anti-microbial filter had been fitted to 
the ET tube. The main targets for ventilation were tidal volume equal to 10ml/ kg and end tidal CO2 
(ETCO2 between 4.5% and 5%. The MBW test session was started by attaching the modified 
pneumotachometer/gas sampling line to the filter and disconnecting the ET tube ETCO2 sampling 
line. ETCO2 was from then until the end of the MBW test session monitored with the Innocor machine. 
The pneumotach/gas line assembly was then attached to a flow-past circuit of air containing 0.2% 
SF6. End expiratory SF6 concentration was monitored in real time on the Innocor screen. The flow-
past was disconnected during expiration once the inspiratory and expiratory SF6 concentration 
difference was less than 0.002%. The Innocor  then continued to record data until the absolute 
expiratory SF concentration was less than 0.002% for more than two consecutive breaths. This 
represented the end of one MBW test. Two further tests were performed immediately after the first. 
The raw data were retrieved from the Innocor hard drive and analysed in a standardised way using 
customised GTC software to integrate the flow and SF6 concentration curves for each breath of each 
MBW to derive FRC and LCI. Assessment was performed immediately prior to the delivery of Dose 9 
and then again immediately prior to PME after the 28day recovery period post-Dose 9.  The sentinel 
group was also assessed immediately prior to PME. 
 
2.6 Sample collection from anaesthetised animals  
 
 Bronchoalveolar lavage (BAL) fluid and bronchial brushing (BBr) samples were collected as 
previously described [3] at the timepoints shown in Fig. 1 and listed in Supplementary Table S2. 
 
2.7 RNA and DNA extraction 
 
 Bronchial brushings (BBr) harvested from the airways at at 1 day after Dose 1, 5 and 9 and 
parenchyma (Tx) and BBr samples taken at post-mortem examination at day 28 after Dose 9 (see 
Necropsy section) were processed for mRNA and DNA analysis. Total DNA and RNA were prepared 
from BBr and Lysing Matrix D-homogenised Tx samples using the AllPrep DNA/RNA Mini kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. DNA was eluted from the AllPrep column 
in 100μl nuclease-free water and final DNA concentrations were quantified with the Quant-
iTPicoGreen dsDNA assay kit (Invitrogen, Paisley, UK). After on-column DNase digestion (Qiagen), 
RNA was eluted from RNeasy columns in 30 – 50μl nuclease free water (Promega, Southampton, 
UK) and then further treated with the DNA-free kit (Ambion) according to manufacturer’s instructions 
in order to ensure complete removal of plasmid DNA. Final RNA concentrations were quantified with 
the Quant-IT RiboGreen RNA assay kit (Invitrogen).  
 
2.8 DNA qPCR analysis 
 
 The sequences of the pGM169 DNA TaqMan assay primers were – forward primer (50nM): 
169_DNA-5095F (5’-GGAACAGCTCCAAGTGCAAGA-3’), reverse primer (900nM): 169_DNA-5174R 
(5’-CCTGGTGTCCTGCACTTCCT-3’), and fluorogenic probe (100nM): 169_DNA-5117A (5’-FAM-
CAAGCCCCAGATTGCTGCCCTG-TAMRA-3’). The oCFTR assay is specific for DNA detection as it 
spans a sequence from intron 3 of oCFTR. The sequences of the oCFTR DNA TaqMan assay 
primers were – forward primer: oCFTRint3-696F (300nM) (5’- TCTTCATGCCTCTGGGAGTGA-3’), 
reverse primer (300nM): oCFTRint3-778R (5’- AGCACAAGTTCTTAAAGCAATGCA-3’) and 
fluorogenic probe (100nM): oCFTRint3-731T (5’-FAM-CTCCCCAAGAGGTGCCCAGCAAG-NFQ-
MGB-3’) (NFQ-MGB is dihydrocyclopyrroloindole tripeptide, a non-fluorescent quencher that binds in 
the minor groove of DNA). Multiplex reactions (both primer sets in each well) were performed in 
quadruplate, each containing 2μl of DNA diluted to 0.5ng/μl (necropsy samples) or 0.05ng/μl (live 
bronchial brushings). PCR and fluorescence detection was performed in a final volume of 10µl 1X 
TaqMan Universal PCR buffer using standard PCR cycling conditions on a TaqMan 7900HT Real 
Time PCR System (Applied Biosystems). Results were analysed using Sequence Detection System 
Software Version 2.3. The experimentally determined copy numbers of pGM169-specific DNA (based 
on a standard curve made from a pGM169 plasmid dilution series) and endogenous oCFTR DNA (on 
a standard curve made from a dilution series of ovine genomic DNA) were used to calculate DNA in 
samples, expressed as %vector/endogenous (copies of pGM169 DNA/copies of ovine CFTR DNA x 
100). 
 
2.9 RNA qPCR analysis 
  Samples were analysed by TaqMan RT-PCR with primers for amplification of both pGM169-
derived mRNA and endogenous oCFTR mRNA as described previously [11], using target-specific 
primer sets [12] except that cDNA synthesis was performed in 10µl (oCFTR) or 20µl (pGM169) 
volumes, incubated at 48°C for 30 minutes and 95°C for 5 minutes in a GeneAmp PCR 2700 System 
(Applied Biosystems), with TaqMan reactions in a final volume of 10µl. Comparator samples included 
those in which lung RNA was replaced with water (no template control), and synthetic RNA standards 
ranging from 5 copies/µl to 78,125 copies/µl input RNA. The pGM169 assay is specific for RNA 
detection as the reverse primer is designed across the intron within the 5’ non-coding sequences of 
pGM169. The ovine CFTR assay is specific for RNA detection as it spans the junction between exons 
1 and 2 of ovine CFTR. PCR and fluorescence detection was performed in a final volume of 10µl 1X 
TaqMan Universal PCR buffer using standard PCR cycling conditions on a TaqMan 7900HT Real 
Time PCR System (Applied Biosystems). Results were analysed using Sequence Detection System 
Software Version 2.2.2 or 2.3 (Applied Biosystems). 
 
2.10 Necropsy  
 
 Following euthanasia by lethal injection and exsanguination, the lungs were removed for tissue 
collection as previously described [3] with a few modifications. The following lung segment 
nomenclature was used: RA, right apical; RI, right intermediate; RC, right cardiac; RVD1, RVD2, right 
ventral diaphragmatic 1and 2; RCD, right caudal diaphragmatic; LC, left cardiac (cardiac segment of 
the apicocardiac lobe); LVD1, LVD2, left ventral diaphragmatic 1 and 2; LCD, left caudal 
diaphragmatic. The pulmonary circulation was flushed out via the pulmonary artery with 2–3 L of PBS 
before sampling. Organ appearance and weights were recorded. BAL samples were collected from 
RCD & LC anterior portion. BBr samples were collected from segments RA-anterior, RA-posterior, 
RC, RI, LC, LVD1, LVD2, LCD. The right side main bronchus was cannulated distal to RI/RC 
segments for inflation fixing of remaining intact right lung (Segments RVD1, RVD2 and RCD) with 
formalin for histology and Massons Trichrome stain. Segments RC and LC were inflated with 
OCT/sucrose and frozen for IHC and Oil Red O stain. Segments RA, LVD1, LCD (AWU, PU, M, L) 
were finely minced and stored in RNALater for DNA and RNA extraction. After 48hr in formalin the 
right lung portion was sliced transversely (~1cm thick) numbered from distal to proximal and four 
blocks selected for histology. These were two blocks from slice 2 (one with airways and one 
parenchyma/pleura) and two blocks from the “middle” slice (one with airways and one 
parenchyma/pleura).  Remaining slices were stored in formalin in case more comprehensive analysis 
was required. One section from each of four different blocks from the inflation fixed right side of the 
lung was examined histologically in a blinded manner.  Samples from other organs were collected as 
described in Table S2. Detailed procedures for sampling heart, liver, kidney, spleen are listed in 
Supplementary Materials & Methods. 
 
2.11 Lung Morphometry  
 
 Masson’s Trichrome stained slides with samples of lung were imaged using an Olympus BX41 
microscope and Olympus Cell ^D Software. Five images of parenchyma from each of two slides per 
sheep at 40x magnification with a set scale of 50um etched onto them were blinded for analysis. The 
Image J programme was used to measure the scale bar and set the known length in pixels for that 
line. Thereafter the length of any line drawn on the image can be calculated. Images were converted 
to binary to allow %black/white to be calculated. Mean linear intercept (Lm), Area Fraction, Septal 
Wall Thickness and number of intersections were calculated. The detailed procedure is described in 
Supplementary Materials & Methods. 
 
2.12 Statistical analysis   
 
 The study essentially consists of self- contained repeated units of 28 days- in terms of the majority 
of the datasets. For every 28 day unit there are; variables measured from observations not requiring 
anaesthesia and variables measured from observations requiring anaesthesia. For the majority of the 
analyses use is made of the statistical technique ‘linear mixed-effect (LME) models‘. This system of 
analyses takes into account the repeated measurements/units from each sheep (with the number of 
units increasing during the study). The use of LME allows for any individual sheep effects to be taken 
into account as a random factor (without, formally, being “penalised” in terms of degrees of freedom). 
Differences between MD_CON, MD_GT and Sentinel animals and differences with increasing doses 
are then evaluated as fixed effects. For analysis of one blood parameter (Total Monocytes), 
normalisation of the residuals was not possible therefore simple non-parametric comparisons were 
carried out as a - Wilcoxon signed rank test for paired (eg Pre v Post), and Mann-Whitney test for two 
groups (e.g. MD_CON versus MD_GT). LME models were also used to evaluate % 
vector/endogeneous from bronchial brushings (BBr) and tissue (Tx) samples. For this analysis the few 
(n=9) positive but not quantifiable (PBNQ) and not determined (ND) observed at D1d1 and D9d1 were 
excluded. For the data from the MBW procedure (LCI & FRC) a one-way ANOVA was carried out with 
standard post hoc Tukey pairwise comparisons considered to look to see where differences between 
groups (MD_CON, MD_GT and sentinels) and time points occurred. The same technique was used to 
look at differences between groups in septal wall thickness and the ratio between lung tissue and 
airspace (Area %).  For mean linear intercept (Lm) the residuals from the ANOVA were not normal so 
the non-parametric equivalent (Kruskal-Wallis and the post hoc Dwass-Steel-Chritchlow-Fligner tests) 
was carried out. In all cases *** p<0.001, ** p<0.01, * p<0.05, , and all analyses were carried out in R 
(v3.0.0 © 2013 The R Foundation for Statistical Computing). The Null Hypothesis was rejected at 
p<0.05.. 
 Graphing conventions. For the BAL cell data (Fig. 3), lung morphometry data (Fig. 7)  and MBW 
data (Fig. S12) each point is the value for a single animal and the bar represents the median value. 
For the plasmid DNA copy number data (Fig. 8) each point represents an individual sample and the 
bar represents the median value. For all the other figures each point represents the mean ± 95% 
Confidence Interval for the anaesthesia only control group, the GL67A/pGM169 treated group and the 
Sentinel group. 
 
 
3. Results 
 
3.1 Dose and delivery 
 
 Three groups of animals (n=8 each) were included in the study. One group received multiple 
doses of the gene therapy formulation (MD_GT); a second group was exposed to multiple periods of 
room air only to control for the repeated anaesthetic periods (MD_CON). Figure 1 illustrates the study 
design for these two groups.  Each monthly 10ml dose contained 26.4mg pGM169 and approximately 
150mg lipid. The average sheep bodyweight over the 9 doses was 54.7kg and thus the average dose 
was 0.5 mg/kg pGM169 and 2.6 mg GL67A / kg . Average delivery time (+/- Standard Deviation (SD)) 
for the MD_GT Group was 67min +/- 9min and the average amount aerosolised (obtained by 
subtracting final weight of nebuliser from starting weight) was 86.2 +/- 1.5% of the 10ml dose. The 
control group (MD_CON) was exposed to room air for 60 min. 
 
3.2 Systemic toxicity parameters 
 
 Physiological and behavioural signs before and after dosing indicated that the repeated delivery 
was well tolerated with no discernible effects on appetite, condition or demeanour. There were no 
consistent differences in body temperature between control (MD_CON) and treated (MD_GT) groups 
(P= 0.107 Fig. S1). In the MD_GT group, the only significant changes in temperature from pre-
treatment to day 1 were after Doses 4 (D4d1) and  6 (D6d1) (median change 0.25°C, p<0.031) but the 
median changes were small and transient (D4d1 +0.5°C, D6d1 +0.25°C).  Animals in both groups 
gained weight at a rate equivalent to each other and to the sentinel animals over the course of the 
study and no differences between MD_GT, MD_CON and sentinels were present at post-mortem 
(P>0.125, Fig. S2). 
 
Red blood cell (RBC) numbers, haemoglobin and peripheral white blood cell (WBC) counts were 
elevated at day 1 post-treatment for each dose in both MD_CON and MD_GT groups (data not 
shown). The increase in WBCs was higher for the MD_GT group (P=0.036), however changes in all 
these parameters were mild and resolved between doses.  As expected, the leucocytosis was 
reflected in significant changes in blood neutrophil numbers (Fig. S3) from pre-treatment to day 1 at 
5/9 doses in MD_GT and 3/9 doses in the MD_CON groups but these changes were small and had 
resolved by the day 15 measurment (P>0.153). These acute changes did not increase in severity with 
successive doses in either group of animals (P>0.343). No consistent or cumulative effect was 
observed on blood monocytes or eosinophils.  
 Significant increases in the serum acute phase reactant haptoglobin were observed again in both 
active and control groups at day 1 post-treatment compared to pre-treatment values (Fig. 2, P<0.049 
in all but the 1
st
 and 9
th
 doses in MD_GT and P<0.026 at doses 1,2,7,9 in MD_CON). These increases 
were slight and had always resolved between each dose (P>0.104). While unexplained sporadic high 
values were observed in three of eight MD_CON animals at D1d15 these did not correspond to an 
acute change post-dosing and were not coincident with changes in any other parameter. Similarly two 
of eight MD_GT animals had elevated levels prior to Dose 1 delivery which persisted at D1d1 (Fig. 2) 
but are unlikely related to dosing.  
 Successive doses of pGM169/GL67A did not lead to consistent or cumulative changes in clinical 
chemistry parameters such as liver enzymes, urea, amylase and electrolytes (data not shown). Serum 
creatinine levels were generally stable over the course of the study (Fig. S4) although a trend towards 
greater delta creatinine (from pre-day1 at each dose) was observed in the MD_GT group  (Linear 
change in successive delta values: P<0.01). Despite this, only ~2% of the measurements were ever 
above the reference range and the levels at day 15 (D9d15) or 4 weeks after the final dose were 
lower than the original baseline for the MD_GT group. 
 
3.3 Bronchoalveolar lavage (BAL) 
 
 BAL was performed at day 1 and at day 15 after Dose 1, 5 and 9 (Fig. 3). In the MD_GT group 
total BAL cell numbers were elevated relative to pre-treatment values at day1 after all doses but only 
significantly at Dose 1 (D1d1: P<0.001) (Fig. 3b): these had resolved by the respective day 15 time 
points. The change from baseline to day 1 in the MD_GT group was not exacerbated at either Dose 5 
or 9 when compared to the change after Dose 1 (P>0.051). The percentage of neutrophils in the BAL 
of the MD_GT group was increased at day 1 following Doses 1, 5 and 9 (all P<0.006) (Fig. 3d): again 
these increases had resolved by day 15 after each dose. The change from baseline to day1 at Dose 5 
was significantly higher than that at Dose 1 (P<0.001) but there was no additional increase at Dose 9 
(P=0.850).  A significant increase in BAL macrophage numbers was also observed in the MD_GT 
group at day 1 after Dose 1 (D1d1)(Fig. 3f) compared to baseline (P<0.001) but macrophage numbers 
also returned to baseline by D1d15.  At the other two time points the BAL macrophage numbers were 
either lower than or not different from baseline. The day 15 values after Dose 1, 5 and 9 in the 
MD_GT group were all lower than baseline (P<0.002) and post mortem examination (PME) values, 4 
weeks after the final dose. were indistinguishable from baseline (P=0.617, Fig. 3f). BAL lymphocytes 
also increased compared to baseline at D1d1 (MD_GT group only:P<0.001: data not shown) but day 
15 values at Dose 1, 5 & 9 were all lower than baseline.  
 
3.4 Lung Function  
 
 Gas transfer (DLCO) increased over the course of each delivery period (Fig. 4a) in both groups 
with no cumulative time-dependent change observed. An overall upward trend was noted in alveolar 
volume (VAeff) measurement in MD_CON and MD_GT animals over the course of the study 
(P<0.001, Fig. S5) and against this background there were occasional decreases over individual 
delivery periods at later doses in both MD_CON (D7, P=0.017) and MD_GT (D5, D7, P<0.028). 
However, no pGM169/GL67A-specific effect was observed. Lung Compliance (Cmlsr: Mean Least 
Squares Regression) also showed a statistically significant overall upward trend in both MD_CON and 
MD_GT (P<0.031, Fig. S6), but again, there was no pGM169/GL67A-specific effect observed in either 
pre- or post-dose data (P>0.175). In contrast, Functional Residual Capacity (FRC) and Lung 
Resistance (Rmlsr) measurements showed no overall time-dependent change (Figs. S7-S8).  
 Changes identified as a consequence of each period of anaesthesia and/or aerosol delivery (Pre-
Post) were consistent between groups. Maximum Expired Flow (MEF) values did not differ between 
MD_CON and MD_GT (Fig S9). While a downward linear trend in successive pre-dose values was 
observed for both groups (P<0.014), there was no effect of the pGM169/GL67A at days 1 or 15, when 
measured after Dose 1, 5 and 9. Pre-dose values for Total Expired Volume (TotExpVol) showed a 
significant linear time-dependent increase over the course of the study in both groups (P<0.003) (Fig. 
S10).  No pGM169/GL67A-related changes were observed in post-treatment measures at day 1 and 
15 after Dose 1,5 or 9. No consistent changes were observed in either group for forced expiratory 
volume in 0.5 s (FEV 0.5) (Fig. S11) but incremental time-dependent decreases were apparent when 
expressed as a fraction of TotExpVol (FVC) (Fig. 4b) in both MD_CON and MD_GT groups. (linear 
change for pre-dose values P<0.001). Overall there were no pGM169/GL67A-related changes in 
expired flow or volume.  
 
3.5 Multiple Breath Washout (MBW)  
 
MBW is a sensitive test of predominantly smaller airways in man [13], and we therefore applied this 
technique for the first time to our sheep model. There was no difference between pre-Dose 9 and the 
28-day recovery values for either the lung clearance index (LCI) (Fig. S12) or the functional residual 
capacity (FRC) data for the MD_GT or MD_CON (P>0.518) and neither group was significantly 
different to the data from the sentinel group (P>0.597) indicating that there was no adverse effect of 
the test item on LCI measurements. 
 
3.6 Histology and lung morphometry  
 
Blinded histopathological analysis revealed no difference between MD_GT, MD_CON and Sentinel 
animals. Some very minor changes were noted in single sheep including rare and mild focal fibrosis 
(Figs. 5a,c ) in a MD_GT animal and mild cellular infiltrates with minimal interstitial fibrosis (Figs. 5b,d) 
in a MD_CON animal, although these were considered to be incidental. Overall there was nothing to 
suggest a harmful consequence of the repeated delivery of pGM169/GL67A. Serial sections from the 
same blocks as the H & E sections above were stained with Masson’s trichrome. Blinded analysis 
confirmed the presence of mild collagen deposition in the previously described areas of fibrosis but 
did not indicate any widespread interstitial fibrosis (Fig. S13). There was no evidence of a consistent 
effect of treatment with pGM169/GL67A. The Oil Red O stain on frozen sections showed distinct red 
staining restricted to peribronchial adipocytes (fat cells) (Fig. S14). The number of fat cells are within 
normal limits and not unexpected in this location. Occasional free red lipid droplets were noted in 
animals from both groups but no red foamy macrophages. Rarely, red droplets were observed in 
some capillaries or in alveolar walls, suggestive of absorption of lipid into the bloodstream but this 
observation was not restricted to the MD_GT group. Overall the Masson’s trichrome and Oil Red O 
stains provided no evidence of a pGM169/GL67A-related effect.  
 Blinded morphometric analysis of slides from all three groups (Fig. 6) found no significant 
differences between the groups in alveolar septal wall thickness (Fig. 6a) or in area fraction (% Area : 
Fig. 6c), a measure of the ratio between lung tissue and airspace. A difference was observed in the 
mean linear intercept (Lm) values (Fig. 6b), an indicator of alveolar size, however it was the MD_CON 
group that had a higher Lm value than both Sentinel  and MD_GT (P<0.031) groups thus no 
pGM169/GL67A specific effect was observed on lung morphometry. On blinded analysis of H & E 
stained sections from heart, kidney, liver and spleen there were no persistent histological lesions 4 
weeks after final delivery that could be attributed to effects of treatment with nine doses of 
pGM169/GL67A (data not shown). 
 
3.7 Molecular Analyses 
 
 Bronchial brushings (BBr) and tissue (Tx) samples were analysed by quantitative PCR for pGM169 
and endogenous ovine CFTR (oCFTR) DNA as well as for pGM169 mRNA and oCFTR mRNA. 
Plasmid pGM169 DNA was detected in all BBr samples from the MD_CON and MD_GT animals (Fig. 
7). However the day 1 post-dose levels of pGM169 DNA in the MD_GT samples were two to three 
orders of magnitude higher than the levels of pGM169 DNA detected in either the MD_CON samples 
(P<0.001) or the preliminary samples from the MD_GT animals (P<0.001). In the MD_GT group at 
necropsy, 53/64 BBr (median value 87% pGM169/oCFTR DNA, 1.58x10
2
 copies/ng DNA) and 77/96 
Tx samples (median value “positive but not quantifiable” either expressed as % pGM169/oCFTR DNA 
or copies/ng DNA) were positive for pGM169 DNA. Ovine CFTR mRNA was detected in 285/288 of 
the MD_CON group and 288/288 of the MD_GT group samples.  
 No pGM169 mRNA was detected in any sheep at any time point in the MD_CON group. Plasmid-
derived gene expression was detected in 12% of BBr samples at day 1 after the first dose, 34% of 
BBr at day 1 after the 5th dose and 12% of BBr at day 1 after the ninth dose. By day 28 after Dose 9, 
only 2/96 lung tissue (Tx) samples had detectable pGM169mRNA and no pGM169 mRNA was 
detected in the BBr. Table 1 indicates the MD_GT samples in which pGM169 mRNA was detected 
1day after each dose.  It is interesting to note that positive BBr samples were obtained from two 
sheep (MD1,MD 16) at Day 1 after doses 1,5, and 9 (12 of the the 19 positive BBr came from these 
two sheep ), from four sheep at one or two of the day 1 timepoints and there were two sheep (MD2, 
MD18) that were always negative at the day 1 timepoints. 
 
4. Discussion 
 
In this study we report for the first time the outcome of nine monthly aerosol administrations of a non-
viral gene therapy formulation, to a large animal model with lungs of a similar size and structure to 
those of humans. We have previously used this model system to compare the efficacy of three gene 
transfer agents in studies [3] that informed the selection of the current candidate formulation for a 
Multi-dose clinical trial in CF patients. The primary goal of these studies was to determine whether the 
mild acute adverse responses observed in our previous studies would lead to cumulative or chronic 
changes in the lung after multiple administrations. In this study, the average dose in the nebuliser was 
0.48mg pGM169/kg and 2.68mg GL67A/kg. This represents an approximately two-fold greater dose 
than is being used in the Multi-dose Trial (based on a 60 kg patient) and approximately 2-fold lower 
than the maximum dose used in previous studies in sheep and humans, with the intent to minimise or 
abolish the mild and transient acute response noted in those studies.  
 Repeated gene delivery by aerosol was well tolerated by the sheep with no obvious clinical signs 
throughout the study. The majority of changes observed were mild and were observed in both 
anaesthetic controls (MD_CON) and treated (MD_GT) animals. For example a small decrease in 
animal bodyweight and increases in haematological parameters such as RBCs, WBCs and 
haemoglobin were observed at day 1 and are likely a consequence of the anaesthetic procedure. The 
overall downward trend in blood lymphocytes and WBC numbers observed in MD_CON and MD_GT 
groups was also seen in the sentinel animals, suggesting that these are normal changes in maturing 
animals. Plasma concentrations of the serum acute phase protein haptoglobin are elevated as part of 
the host innate immunity in response to inflammatory cytokines and therefore are indicative of 
inflammation. The increases in haptoglobin observed at day 1 after delivery were also observed in the 
MD_CON group and were less than 2-fold  suggesting a mild response to the anaesthetic procedure 
rather than to the gene transfer agent as changes of more than 50-fold have been reported in 
response to lung damage in sheep [14]. All of these changes resolved and were not exaggerated by 
repeated dosing.  
 The absence of a gene transfer-specific increase in haptoglobin in the current study using a 10 ml 
aerosolised dose contrasts with our previous results demonstrating a significant gene transfer agent 
effect with a 20ml aerosolised dose of pDNA/GL67A complex [3] and suggests that the lower dose 
has an improved safety profile. Although a significant upward trend was observed in serum creatinine 
levels from pre-treatment to day 1 in the MD_GT group the absolute increase in values was relatively 
small, the majority of the values (~98%) being within the normal reference range for sheep (40-
150µmol/l) and the final values after the 4 week recovery period were lower than the baseline levels. It 
is important to note that none of the mild post–dose changes increased in severity with successive 
doses.  
 The main area in which gene transfer-specific effects were observed was in relation to changes in 
BAL cellularity measured after Doses 1, 5 and 9. BAL was only performed at these time points to limit 
the number of anaesthetic periods during the study.  Changes in cellularity manifested as increases in 
total BAL cell number, the percentage of neutrophils, total macrophages and total lymphocytes. 
Importantly, responses were not exaggerated by repeated delivery and the observed changes had 
always fully resolved by day 15 after a delivery. The magnitude of the changes in BAL cells after nine 
doses was not more severe than those previously observed in the sheep lung at day 1 after a single 
20ml (~1 mg  /kg / dose pDNA and ~5.2mg GL67A / kg / dose) dose [3].  Interestingly, although the 
percentages of macrophages and lymphocytes in the BAL always showed a decrease due to the 
large increase in neutrophils, an increase in absolute BAL macrophage and lymphocyte numbers was 
observed but only after Dose 1. Unlike previous studies in the mouse [2], delivery of CpG-free 
plasmid/lipid complexes to the sheep lung did not completely abolish the transient inflammatory cell 
response in BAL samples. Similarly, the use of CpG-free plasmid DNA did not completely eliminate 
the mild and transient “flu-like” symptoms observed in patients [4] and suggests that sheep may be 
more similar to humans in terms of responses to pDNA/lipid delivery, than mice. 
 Lung function parameters (DLCO, VAeff, FRC, Compliance, Resistance) measured immediately 
pre- and post-delivery showed no changes attributable to delivery of pGM169/GL67A. Mild changes 
were observed either as a response to the anaesthetic/ventilation period or perhaps as a 
consequence of normal development/maturation of the lungs over the course of the study. For 
example, gas transfer (DLCO) might have been expected to decrease if lung function was 
compromised by delivery; DLCO actually increased during each delivery period in both groups. The 
mechanism for this increase is unknown but we speculate that an increase in pulmonary capillary 
blood volume associated with whole body negative pressure ventilation may contribute to this 
phenomenon. Forced expiration analysis also demonstrated that there were no pGM169/GL67A 
treatment-related effects on the animals. Changes such as the steady increase in total expired 
volume (TotExpVol or FVC) over time, the consequent “decline” in FEV 0.5 when expressed as a 
proportion of TotExpVol (FVC) or the overall decline in MEF, were observed in both groups.  
 These findings may also be a consequence of normal development/maturation in the lung since 
the final values after the 4-week recovery period were not different to those of the sentinel group. 
Animal welfare considerations precluded a more acute evaluation of spirometry that would align with 
data available from clinical trials. Such clinical data indicate a drop in FEV1 in patients over the 6 
hours following delivery that resolves by day 1 [4]. Lung Clearance Index is known to be elevated in 
CF patients with normal spirometry and therefore is believed to be a more sensitive predictor of 
deteriorating lung function, particularly in the smaller airways [13]. Multiple Breath Washout analysis 
to derive LCI values was performed on animals immediately prior to delivering Dose 9 and again after 
the 4-week recovery period at the end of the study. There were no significant differences in the LCI or 
FRC data obtained from this protocol between the MD_CON, MD_GT and sentinel groups. 
 The overall conclusion from histological analysis at 4 weeks after the final dose indicated that there 
was nothing to suggest a harmful consequence of the repeat deliveries and the associated acute 
neutrophilic response noted in the BAL. In the lungs, minimal/mild lymphoplasmacytic (and 
sometimes eosinophilic) inflammation was observed around bronchioles and some blood vessels. 
Mild to moderate bronchus-associated lymphoid tissue (BALT) hyperplasia was also observed but 
these features were not confined to MD_GT animals and are consistent with background 
immunosurveillance and/or indicative of previous parasite exposure. Alveolar histiocytosis was also 
common to all three groups (four in the Sentinel group, five in the MD_CON group and six in the 
MD_GT group). These macrophages were very occasionally mildly vacuolated but were not distinctly 
foamy. Mild alveolar histiocytosis is not unusual in the ovine lung, especially, as in this case, when the 
sheep are not specific pathogen free (SPF) animals, or maintained in climate- or pathogen-controlled 
housing.  
 There were no notable features observed on slides stained with Oil Red O to suggest an 
accumulation of lipid related to treatment.  In contrast in a parallel murine study the high-dose (13.1 
mg pGM169 / kg / dose and 74 mg GL67A / kg / dose) and medium-dose (4.6 mg pGM169 / kg / dose 
and 26 mg GL67A / kg / dose) treated animals showed red foamy macrophages persisting after 12 
doses of pGM169/GL67A (EWFW Alton et al, manuscript submitted) These doses in mice represent 
an approximate overage of 60- and 20-fold relative to the anticipated human dose (based on a 60 kg 
patient) for the high and medium dose cohorts, respectively. In keeping with the current study red-
stained foamy macrophages were not observed in mice treated with the lowest dose 1.2mg pGM169 / 
kg / dose and 6.7 mg GL67A / kg / dose which is still over two-fold higher than the dose administered 
to the sheep (0.5mg pGM169 / kg / dose and 2.6mg GL67A / kg / dose).  
 Other changes noted included occasional and mild localised pleural fibrosis (to the same extent in 
all groups), likely due to resolving pleuritis. Similarly, there was no adverse effect of repeated gene 
delivery observed on lung morphometry in terms of changes in alveolar septal thickness or alveolar 
size to indicate remodelling. In the sections from heart, kidney, liver and spleen, there was nothing to 
indicate an adverse effect of treatment. Lesions present in all groups were likely incidental and 
consistent with background inflammation or immunosurveillance. 
 We have previously shown that this method of delivery results in widespread deposition of plasmid 
in the lung. Despite the presence of environmental pGM169 leading to contamination of pre-treatment 
and MD_CON samples during sample harvesting and/or processing, pGM169 DNA was clearly 
detectable well above background in all post-treatment BBr samples at day 1 after each dose, and in 
the majority of samples at day 28 after the final dose. There was no evidence of pGM169 DNA 
accumulation in the lung, with increasing doses of pGM169/GL67A. Plasmid-derived hCFTR mRNA 
was detected in BBr after all doses but expression levels even after repeated administration remained 
comparatively low and did not appear to persist when analysed 28 days after Dose 9. These results 
contrast with data obtained in mice following delivery of pDNA with the luciferase reporter gene driven 
by the same promoter where a  persistent level of gene expression was observed beyond the 28-day 
timepoint [2] and in humans where prolonged correction of the chloride transport defect was observed 
[4]. These differences could be due to species-specific effects in the performance of the hCEFI 
promoter/enhancer, in efficiency of gene delivery, or in the type or location of cell samples harvested 
for analysis. Such differences could also be due to the difficulty in detecting vector-specific transcripts 
following gene transfer. The proportion of samples testing positive for plasmid-derived mRNA in other 
published clinical trials that have delivered plasmid DNA with GL67A have reported similar difficulties 
[6, 15], even when there is evidence of functional correction [5].  Positive mRNA samples were 
consistently generated from two of the eight individual sheep at day 1 following Dose 1, 5 and 9 and 
four animals were positive at some but not all of the day 1 timepoints. The remaining two sheep gave 
no positive results ; this may suggest, as appears to be the case for humans, that perhaps 
unsurprisingly in an outbred population, there are individuals that are more susceptible to gene 
transfer than others.  
 5. Conclusions 
 
 Inhalation exposure of sheep to nine doses of pGM169/GL67A aerosol was well tolerated with no 
clinical symptoms.  The gene expression data suggests inherent differences in susceptibility between 
individual animals and understanding this ‘stratified’ response, if reproduced in the Multidose Trial in 
CF patients, may be crucial in the progression of clinically relevant non-viral gene transfer. The safety 
data indicate that the only test item-related local effect in the lung was the increase in BAL 
neutrophils. This response has been described previously and remains despite the use of CpG-free 
plasmid DNA. Importantly, the BAL neutrophil response observed after 9 doses is no more severe 
than that observed after a single dose and had resolved within 15 days.  Any observed changes in 
lung function or spirometry were also observed in control animals therefore likely reflect an effect of 
the prolonged anaesthetic period or normal lung maturation in developing animals. Lung clearance 
index values in treated animals were no different to controls. Histological analysis revealed no 
changes related to repeated administration and no accumulation of lipid in macrophages. Parameters 
such as bodyweight, haematology or clinical chemistry gave no indication of a systemic response to 
repeat administration of pGM169/GL67A, Overall there were no adverse responses observed that 
would undermine confidence in progressing towards a similar Multidose study in CF patients. 
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Captions 
Fig. 1. Diagram illustrating study outline. Where practical, measurements and observations were performed 
immediately before (Pre-) and immediately after (Post-) each delivery period. Sampling procedures not requiring 
anaesthetic were performed at day 1 following every delivery. Arrows indicate deliveries or invasive sampling 
days involving anaesthetic.  Broken arrow: Baseline, Black arrows: pGM169/GL67A delivery (MD_GT Group) or 
anaesthetic only (MD_CON group). Grey Arrows: d1 Sampling (Invasive). Arrowheads: d15 Sampling. White 
Arrow: Necropsy. 
 
Fig.2. Plot showing longitudinal serum haptoglobin levels in: anaesthetic control (MD_CON), pGM169/GL67A 
(MD_GT) and Sentinel (SEN; D1d1, D5d1, D9d1 & PME only) animals. Symbols represent group mean +/- 95% 
CI. Baseline : 4 weeks before dose 1. Pre : immediately before delivery. d1 : one day after delivery. d15 : 15 days 
after delivery. PME : end of 4-week recovery period from dose 9. 
 
Fig. 3. Scatterplots showing bronchoalveolar lavage cell data in anaesthetic control (MD_CON) (a, c, e) and 
pGM169/GL67A (MD_GT) (b, d, f) animals. Figures show data for total BAL cells (a,b), % Neutrophils (c,d) and 
macrophage numbers (e,f). Symbols represent individual animal values: bar represents group mean. Pre1: 4 
weeks before dose 1. d1: one day after delivery. d15: 15 days after delivery. PME: end of 4-week recovery period 
from dose 9.  
 
Fig. 4. Plot showing longitudinal lung function data for anaesthetic control (MD_CON), pGM169/GL67A (MD_GT) 
and Sentinel (SEN;  PME only) animals. (a) Gas Transfer (DLCO (SB)) factor (b) Forced Expiratory Volume 
(FEV0.5) as proportion of FVC.Symbols represent group mean +/- 95% CI. Pre: immediately before delivery. 
Post: immediately after delivery. d1: 1 day after delivery. d15: 15 days after delivery. PME: end of 4-week 
recovery period from dose 9.  
 
Fig. 5. Haematoxylin and eosin-stained sections from lungs illustrating some of the minor and focal changes 
observed in single animals from the pGM169/GL67A-treated (MD_GT; a,c) and anaesthetic control (MD_CON; 
b,d) sheep 4 weeks after the final dose. Panel (c) is ahigher magnification of the rare foci of fibrosis (arrow) from 
inset in panel (a). Panel (d) is a higher magnification of the mild cellular infiltrate containing macrophages and 
neutrophils (arrows) from inset in panel (b). Scale bars. (a,b) 200µm, (c,d) 100 µm, 
 
Fig. 6. Scatterplots showing lung morphometry data from Masson’s Trichrome stained sections of lung from 
anaesthetic control (MD_CON), pGM169/GL67A (MD_GT) and Sentinel animals. Individual plots show septal 
wall thickness (a) mean linear iIntercept (b) and area fraction (c). Symbols represent individual animal values. 
Bar represents group mean.  
 
Fig. 7. Plot showing levels of pGM169 DNA as a percentage of endogenous oCFTR DNA in 
live brushing samples (Live BBr) or brushings (BBr) and tissue (Tx) samples harvested at post-mortem. 
MD_CON: anaesthetic control, MD_GT: pGM169/GL67A. Symbols represent individual bronchial brushing (BBr) 
or Tissue (Tx) sample values. Black bars represents group median. Pre = 4 weeks before dose 1. d1: 1 day after 
delivery. d28: 28 days after delivery of dose 9. PBNQ = positive but not quantifiable. ND: not determined. 
 
  
Table 1. Summary of samples positive for pGM169 mRNA in individual animals at each of the 
time-points sampled in the pGM169/GL67A-treated animals (MD_GT) 
 
Brushings Tissue 
Sheep ID D1d1 (32) D5d1 (32) D9d1 (32) D9d28 (64) D9d28 (96) 
MD1 2 2 2 0 0 
MD2 0 0 0 0 1 
MD3 1 2 0 0 0 
MD4 0 1 0 0 0 
MD16 1 4 1 0 0 
MD18 0 0 0 0 0 
MD19 0 1 0 0 0 
MD24 0 1 1 0 1 
TOTAL 4 11 4 0 2 
Median LLQ 0.63% 0.88% 0.24% 0.13% 0.11% 
No samples were positive for pGM169 mRNA in the pre-treatment samples or at any time-point in the anaesthetic 
control group (MD_CON). D1d1 = dose 1 day 1, D5d1 = dose 5 day 1, D9d1 = dose 9 day 1, D9d28 Dose 9 day 
28. MD denotes animal identification number for the study. Figure in brackets represents the total number of 
samples analysed. 
LLQ: lower limit of quantification (pGM169 mRNA as a percentage of endogenous CFTR mRNA) 
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